A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Hyperkalemia

In brief

This clinical trial consists of 2 parts, Part A and Part B. Part A consists of a 2-day randomized, double-blind, placebo-controlled corrective phase (CP) and a 28-day randomized, double-blind, placebo-controlled maintenance phase (MP). Part B (open-label extension, OLE) is an open-label, 11-month extension study carried out in participants who come from Part A and meet certain inclusion criteria.

Key facts

Study ID

NCT07251309

Run by

Waterstone Pharmaceutical (Wuhan) Co., LTD.

People needed

420

Starts

2024-12-23

Expected to finish

2026-11-01

Last updated by the study team

2025-11-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (male or female) aged 18 years and older;
• Participants with a serum potassium concentration >5.0 mmol/L and ≤6.5 mmol/L (serum potassium concentration will be measured using the i-STAT portable biochemical analyzer in screening period);
• Participants who have negative pregnancy test result at screening and ensure the use of contraception during the trial;
• Participants who understand and voluntarily sign the Informed Consent Form.

You may not qualify if…

• Participants who have a history of severe drug allergy, or are definitely allergic to the investigational product or its ingredients;
• Participants who have pseudohyperkalemia, such as serum potassium increasing caused by hemolysis of blood samples due to improper blood collection methods (such as too tight pressure pulse band banding, too heavy local rubbing, repeated fist clenching-loosening hands), hemolysis of blood samples due to difficulty in venipuncture or trauma, and severe leukocytosis (>50 × 10\^9/L) or thrombocytosis (>500 × 10\^9/L);
• Participants with acute hyperkalemia caused by conditions such as tumor lysis syndrome or hemolysis and so on;
• Participants suffering from severe cerebrovascular diseases, such as cerebral infarction or cerebral hemorrhagic disease, with language disorder or unresponsiveness, or severely blocked limb movement;
• Participants who have suffered from myocardial infarction, or have undergone interventional cardiac procedures or coronary artery bypass grafting for coronary atherosclerotic heart disease within 3 months prior to screening; or participants who have heart failure and are in cardiac function class IV (New York Heart Association, NYHA classification criteria) at screening;
• Participants with cardiac arrhythmia requiring urgent treatment at screening, such as ventricular tachycardia, ventricular fibrillation, II-III degree atrioventricular block, severe bradycardia (heart rate <40 bpm), or participants with significant prolongation of PR interval (PR interval prolonged to more than 0.25 seconds in the absence of pre-existing atrioventricular block), decrease or disappearance of P wave amplitude, and widening of QRS wave (widening to more than 0.14 seconds in the absence of pre-existing bundle branch block) indicated by the electrocardiogram at screening;
• Participants who have previously undergone major gastrointestinal surgery such as subtotal gastrectomy, short bowel syndrome and other diseases affecting the normal peristalsis of the gastrointestinal tract; or participants with intractable constipation;
• Participants who have received treatment with polypropylene exchange resin or sodium zirconium cyclosilicate and other similar drugs within 3 days before screening;
• Participants who participated in other clinical trials of drugs or devices not approved for marketing within 3 months prior to the first dose;
• Participants who are receiving dialysis;
• Participants with severe hepatic impairment: serum alanine aminotransferase or aspartate aminotransferase more than 3 times the upper limit of normal;
• Participants who are unable to complete this part of the trial as assessed by the investigator due to any other disease or psychiatric condition; or participants whose participation in the trial is assessed by the investigator as having a risk that far outweighs the benefit.

Where it is running

• Investigator Site 02 — Bengbu, Anhui, China (enrolling)
• Investigator Site 03 — Wuhu, Anhui, China (enrolling)
• Investigator Site 48 — Chongqing, Chongqing Municipality, China (enrolling)
• Investigator Site 04 — Xiamen, Fujian, China (enrolling)
• Investigator Site 05 — Lanzhou, Gansu, China (enrolling)
• Investigator Site 07 — Guangzhou, Guangdong, China (enrolling)
• Investigator Site 06 — Zhanjiang, Guangdong, China (enrolling)
• Investigator Site 08 — Huizhou, Guangxi, China (enrolling)
• Investigator Site 09 — Nanning, Guangxi, China (enrolling)
• Investigator Site 10 — Nanning, Guangxi, China (enrolling)
• Investigator Site 11 — Guiyang, Guizhou, China (enrolling)
• Investigator Site 12 — Haikou, Hainan, China (enrolling)
• Investigator Site 13 — Shijiazhuang, Hebei, China (enrolling)
• Investigator Site 18 — Daqing, Heilongjiang, China (enrolling)
• Investigator Site 15 — Nanyang, Henan, China (enrolling)
• Investigator Site 16 — Nanyang, Henan, China (enrolling)
• Investigator Site 14 — Puyang, Henan, China (enrolling)
• Investigator Site 25 — Xinxiang, Henan, China (enrolling)
• Investigator Site 21 — Huangshi, Hubei, China (enrolling)
• Investigator Site 20 — Shiyan, Hubei, China (enrolling)
• Investigator Site 19 — Wuhan, Hubei, China (enrolling)
• Investigator Site 22 — Wuhan, Hubei, China (enrolling)
• Investigator Site 24 — Hengyang, Hunan, China (enrolling)
• Investigator Site 17 — Yueyang, Hunan, China (enrolling)
• Investigator Site 23 — Zhuzhou, Hunan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.